ACELYRIN, INC. (SLRN)
(Delayed Data from NSDQ)
$4.78 USD
-0.03 (-0.62%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $4.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SLRN 4.78 -0.03(-0.62%)
Will SLRN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SLRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLRN
ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study
ACELYRIN (SLRN) Fails to Meet Goal in HS Study, Stock Down 54%
SLRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SLRN
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
ACELYRIN, INC.: Hold Rating Maintained Amid Strategic Pipeline Shift and Extended Cash Runway
Acelyrin price target lowered by $7 at Morgan Stanley, here's why
Mars buys Kellanova, Cardinal Health reports Q4 beat: Morning Buzz
Strategic Realignment Fuels Buy Rating for ACELYRIN, INC.